Compare CBAN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | DCTH |
|---|---|---|
| Founded | 1975 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.6M | 363.5M |
| IPO Year | 1995 | 2015 |
| Metric | CBAN | DCTH |
|---|---|---|
| Price | $19.72 | $11.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | ★ 307.7K | 262.9K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 16.91 | ★ 107.53 |
| EPS | ★ 1.59 | 0.07 |
| Revenue | N/A | N/A |
| Revenue This Year | $35.41 | $24.54 |
| Revenue Next Year | $4.84 | $33.15 |
| P/E Ratio | ★ $12.35 | $164.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.63 | $8.12 |
| 52 Week High | $21.61 | $18.23 |
| Indicator | CBAN | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 62.60 |
| Support Level | $19.12 | $10.50 |
| Resistance Level | $21.21 | $11.99 |
| Average True Range (ATR) | 0.53 | 0.43 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 18.53 | 77.91 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.